Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJAOA101
- Development stage
- Phase 1
- Lead developer
- Tongji Hospital
- Administration
- Oral
01
Overview
**TJAOA101** is an investigational Chinese herbal formula developed at Tongji Hospital for ovarian aging-related disorders. It is being evaluated in prospective multicenter, before-after clinical studies for diminished ovarian reserve and premature ovarian insufficiency. Public records describe it as a traditional Chinese medicine recipe intended to improve ovarian function, but do not disclose its full herbal composition, molecular targets, or a defined pharmacologic mechanism. ([link.springer.com](https://link.springer.com/content/pdf/10.1007/s11596-023-2733-6.pdf))
- Other names
- TJAOA Chinese herbal compound 101Tongji anti-ovarian aging 101
Beyond the preview
Go deeper on TJAOA101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJAOA101.